![]() | |
Clinical data | |
---|---|
Other names | GFT505, SureCN815512 |
ATC code | |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
ChemSpider | |
UNII | |
Chemical and physical data | |
Formula | C22H24O4S |
Molar mass | 384.49 g·mol−1 |
3D model (JSmol) | |
| |
|
Elafibranor (INN,[2] code name GFT505) is an experimental medication that is being studied and developed by Genfit for the treatment of cardiometabolic diseases including diabetes, insulin resistance, dyslipidemia, and non-alcoholic fatty liver disease (NAFLD).[3][4][5]
Elafibranor is a dual PPARα/δ agonist.[6][7]